Sandbox:MGS: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}{{AE}} {{MGS}}
{{CMG}}{{AE}} {{MGS}}


{| class="wikitable"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px"
! style="font-weight: bold;" | Treatment Regimen
|valign=top|
! style="text-align: center; font-weight: bold;" | Drug
|+
! style="text-align: center; font-weight: bold;" | Side effects
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Treatment Regimen}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Drugs}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Side effects}}
|-
|-
| CHOP-R regimen
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''CHOP-R regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Cyclophosphamide
*Cyclophosphamide
*Doxorubicin
*Doxorubicin
Line 15: Line 18:
*Prednisone
*Prednisone
*Rituximab
*Rituximab
|  
| style="padding: 5px 5px; background: #F5F5F5;" |
*Nausea
*Nausea
*Alopecia
*Alopecia
*Granulocytopenia
*Granulocytopenia
|-
|-
| Ibrutinib
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''Ibrutinib'''
---
| style="padding: 5px 5px; background: #F5F5F5;" |
|  
*Ibrutinib
| style="padding: 5px 5px; background: #F5F5F5;" |
*Fatigue
*Fatigue
*Cytopenia
*Cytopenia
|-
|-
| Rituximab
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''Rituximab'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Rituximab
*Rituximab
|  
| style="padding: 5px 5px; background: #F5F5F5;" |
*Infusion related reaction
*Infusion related reaction
*Infections
*Infections
|-
|-
| FR regimen
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''FR regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Fludarabine
*Fludarabine
*Rituximab
*Rituximab
|  
| style="padding: 5px 5px; background: #F5F5F5;" |
*Neutropenia (63%)
*Neutropenia (63%)
*Thrombocytopenia
*Thrombocytopenia
*Pneumonia
*Pneumonia
|-
|-
| BDR regimen
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''BDR regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Bortezomib
*Bortezomib
*Dexamethasone
*Dexamethasone
*Rituximab
*Rituximab
|  
| style="padding: 5px 5px; background: #F5F5F5;" |
*Peripheral Neuropathy - reversible in 61% of patients
*Peripheral Neuropathy - reversible in 61% of patients
|-
|-
| DRC regimen
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''DRC regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Dexamethasone
*Dexamethasone
*Rituximab
*Rituximab
*Cyclophosphamide
*Cyclophosphamide
|  
| style="padding: 5px 5px; background: #F5F5F5;" |
*Neutropenia
*Neutropenia
|-
|-
| CR regimen
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
|  
'''CR regimen'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Cladribine
*Cladribine
*Rituximab
*Rituximab
|  
| style="padding: 5px 5px; background: #F5F5F5;" |
*Anemia
*Anemia
*Neurological symptoms
*Neurological symptoms

Revision as of 18:27, 17 November 2015

Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sandbox:MGS On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox:MGS

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox:MGS

CDC on Sandbox:MGS

Sandbox:MGS in the news

Blogs on Sandbox:MGS

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Sandbox:MGS

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Treatment Regimen Drugs Side effects

CHOP-R regimen

  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
  • Rituximab
  • Nausea
  • Alopecia
  • Granulocytopenia

Ibrutinib

  • Ibrutinib
  • Fatigue
  • Cytopenia

Rituximab

  • Rituximab
  • Infusion related reaction
  • Infections

FR regimen

  • Fludarabine
  • Rituximab
  • Neutropenia (63%)
  • Thrombocytopenia
  • Pneumonia

BDR regimen

  • Bortezomib
  • Dexamethasone
  • Rituximab
  • Peripheral Neuropathy - reversible in 61% of patients

DRC regimen

  • Dexamethasone
  • Rituximab
  • Cyclophosphamide
  • Neutropenia

CR regimen

  • Cladribine
  • Rituximab
  • Anemia
  • Neurological symptoms
  • Symptomatic cryoglobulinemia
  • Thrombocytopenia


References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:MGS&oldid=1188084"